Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
However, newer medications target multiple metabolic hormones: GLP-1 drugs (single-hormone): semaglutide medications like Wegovy and Ozempic Dual-agonist drugs: tirzepatide medications like Mounjaro and Zepbound (target GLP-1 and GIP receptors) Triple-agonist drugs: retatrutide (targets GLP-1, GIP and glucagon receptors) Researchers believe stimulating multiple hormone pathways may produce stronger effects on appetite, metabolism and energy expenditure
It has a longer prescribing history in the UK than Mounjaro and is approved for both NHS and private use, subject to clinical eligibility
Journal of Enzyme Inhibition and Medicinal Chemistry 30, 981-988
Cigna is acting like about 95% of employers that the PSG report says cover GLP-1 drugs for those with Type 2 diabetes
US$ 20.12
US$ 24.12
US$ 24.50
US$ 28.45
US$ 24.03
